What is Organon's brenzys — revenue?

Organon (OGN) reported brenzys — revenue of $20M in Q1 2026.

How has Organon's brenzys — revenue changed year-over-year?

Organon's brenzys — revenue increased by 42.9% year-over-year, from $14M to $20M.

What is the long-term trend for Organon's brenzys — revenue?

Over 4 years (2021 to 2025), Organon's brenzys — revenue has grown at a 6.2% compound annual growth rate (CAGR), from $63M to $80M.

What does brenzys — revenue mean?

This metric represents the total gross sales generated by the Brenzys product line, a biosimilar therapy within the company's portfolio. It serves as a key indicator of market adoption and competitive performance for this specific therapeutic asset. Tracking these revenues helps investors assess the growth trajectory and commercial viability of the biosimilars segment.

Organon OGN Brenzys — Revenue

Other product segments

Nexplanon/Implanon NXT

$201M-19.0%

Other

$87M+11.5%

Zetia

$87M+2.4%

Atozet

$85M+10.4%

Other Non-Opiod Pain, Bone and Dermatology

$68M0.0%

Hadlima

$67M+42.6%

Nasonex

$65M-9.7%

Follistim AQ

$61M-11.6%

Arcoxia

$59M-4.8%

Cozaar/Hyzaar

$57M+3.6%

Renflexis

$57M0.0%

Emgality

$54M+68.8%

Other Women's Health

$46M+7.0%

Singulair

$40M-45.9%

Diprospan

$35M+16.7%

Dulera

$35M-18.6%

Clarinex

$31M-8.8%

Propecia

$30M+15.4%

Fosamax

$29M-12.1%

Other Cardiovascular

$28M-6.7%

Ganirelix Acetate Injection

$26M-3.7%

Marvelon/Mercilon

$26M-33.3%

Proscar

$26M+8.3%

Vtama

$25M+4.2%

NuvaRing

$24M+9.1%

Other Biosimilars

$24M—

Vytorin

$21M-8.7%

Other Respiratory

$12M-7.7%

Rosuzet

$6M+50.0%

Jada

$5M-66.7%

Ontruzant

$5M-72.2%

Similar metrics at other companies

BMYBreyanzi — Total Revenues

$411M+56.3%

BMYReblozyl — Total Revenues

$555M+16.1%

AMRXBiosimilar — Net revenue

$22.3M-21.9%

AMGNENBREL — Total revenues

$320M-37.3%

BMYCobenfy — Total Revenues

$56M+107%

BMRNBRINEURA — Total revenues

$47.1M+16.7%

Other financials

Income statement

See full

Revenue$1.5B-3.5%

Gross profit$783.0M-6.9%

Net income$146.0M+67.8%

EPS (diluted)$0.55+66.7%

Balance sheet

See full

Cash & equivalents$1.1B+104%

Total debt$8.6B-4.3%

Total equity$903.0M+66.6%

Total assets$13.0B-1.2%

Cash flow

See full

Operating cash flow$225.0M+200%

CapEx$37.0M+15.6%

Free cash flow$188.0M+337%

Valuation

See full

Market cap$3.53B-59.4%

Profitability

See full

Gross margin52.8%-4.4pp

Net margin8%-12.3pp

FCF margin11.1%-1.3pp

Returns & leverage

See full

Return on equity71.6%—

Debt / equity9.5×-7.0×

Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's brenzys — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Organon's brenzys — revenue?: Organon (OGN) reported brenzys — revenue of $20M in Q1 2026.
How has Organon's brenzys — revenue changed year-over-year?: Organon's brenzys — revenue increased by 42.9% year-over-year, from $14M to $20M.
What is the long-term trend for Organon's brenzys — revenue?: Over 4 years (2021 to 2025), Organon's brenzys — revenue has grown at a 6.2% compound annual growth rate (CAGR), from $63M to $80M.
What does brenzys — revenue mean?: This metric represents the total gross sales generated by the Brenzys product line, a biosimilar therapy within the company's portfolio. It serves as a key indicator of market adoption and competitive performance for this specific therapeutic asset. Tracking these revenues helps investors assess the growth trajectory and commercial viability of the biosimilars segment.